SOCS3 downregulation may lead to enhanced activity of pro-inflammatory IL6 family cytokines through its reduced ability to interact with gp130 (56) to modulate IL6 signaling, also potentially contributing to SS pathogenesis. This evidence concerns the gene SOCS3 and synovial sarcoma.